Carl O Landgren
University of Miami · Professor of Medicine · National Cancer Institute (NCI)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Carl O Landgren as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:58 UTC. Open this list on ClinicalTrials.gov
- N/ANCT07446777 · FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor DiseaseUniversity of Miami · recruiting · Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma · principal investigator
- Ph2NCT06997081 · ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)University of Miami · recruiting · Multiple Myeloma · principal investigator
- Ph2NCT06100237 · Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)Carl Ola Landgren, MD, PhD · recruiting · Multiple Myeloma · principal investigator
- Ph2NCT05896228 · Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple MyelomaBenjamin T Diamond, MD · recruiting · Refractory Multiple Myeloma, Relapsed Multiple Myeloma · principal investigator
- Ph2NCT01660997 · MLN9708 and Dexamethasone for High-Risk Smoldering Multiple MyelomaNational Cancer Institute (NCI) · withdrawn · Multiple Myeloma · principal investigator
- Ph2NCT01647165 · Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib MaintenanceNational Cancer Institute (NCI) · withdrawn · Multiple Myeloma · principal investigator
- Ph2NCT01571726 · Imaging Studies and the Development of Multiple MyelomaNational Cancer Institute (NCI) · withdrawn · Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:58 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 4 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Translational and Clinical Oncology Research ProgramP30CA240139 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · fiscal years 2024 to 2026 · $32,537 awarded in 2026Same name and institution; not confirmed by an ID
- Molecular and clinical profilingZIABC011352 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2010 to 2011 · $1,125,632 awarded in 2011Same name and institution; not confirmed by an ID
- Population based studiesZIABC011205 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2009 to 2011 · $198,641 awarded in 2011Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:58 UTC. The ranking covers the 200 most relevant of 6 PubMed records, and a shared surname and initials can bring in a namesake. All 6 on PubMed
- CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging.Radiology · 202097 citationsRCR 4.9
- 91 citationsRCR 3.6
- Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance.Biol Blood Marrow Transplant · 201839 citationsRCR 1.4
- Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis.Biol Blood Marrow Transplant · 202013 citationsRCR 0.6
- Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma.Leuk Lymphoma · 201811 citationsRCR 0.3